In this article, we will list the 5 Best Healthcare Stocks to Buy with Highest Upside Potential. Please visit 10 Best Healthcare Stocks to Buy with Highest Upside Potential if you would like to see the extended list and the methodology behind it.

5. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Analyst Upside: 42.76%

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best healthcare stocks to buy with highest upside potential. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on May 28 that maftivimab has been recommended by the World Health Organization’s (WHO) Therapeutics Advisory Group to be prioritized for evaluation in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab is the most potent neutralizing antibody included in Inmazeb®, according to the company, and has exhibited broad activity in vitro against multiple Ebola species, including Bundibugyo.

Management further reported that the trial relates to the recent declaration by the WHO that the current outbreak of Ebola disease caused by Bundibugyo virus in Uganda and the Democratic Republic of the Congo (DRC) constitutes a public health emergency of international concern.

In another development, Canaccord cut the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $875 from $1,057 on May 19, maintaining a Buy rating on the shares. The firm updated its model on the stock after its Phase 3 study of fianlimab+cemiplimab vs pembrolizumab failed to hit statistical significance on the primary endpoint of progression-free survival (PFS), which it considered a surprising and disappointing event.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a pharmaceutical company that develops, discovers, and commercializes therapies for several diseases, including cancer, eye disorders, and allergic conditions.

4. Medtronic plc (NYSE:MDT)

Analyst Upside: 45.99%

Medtronic plc (NYSE:MDT) is one of the best healthcare stocks to buy with highest upside potential. On May 21, Goldman Sachs reinstated coverage of Medtronic plc (NYSE:MDT) with a Neutral rating and set a $84 price target on the stock, which offers 7.5% upside potential. The firm told investors in a research note that the shares at current levels offer a balanced risk/reward, trading at a 10% discount to Medtronic’s large-cap medical technology peers. Goldman Sachs added that it wants to see improving revenue and earnings growth before recommending the shares.

In a separate development, Medtronic plc (NYSE:MDT) announced on May 20 its intention to acquire SPR Therapeutics, Inc. (SPR), which is a privately held medical technology company that holds a leading position in temporary, percutaneous peripheral nerve stimulation therapies for chronic pain management. Management stated that the transaction comprises an upfront cash payment of approximately $650 million for all the outstanding equity in SPR, and is subject to customary closing conditions and regulatory approvals.

Medtronic plc (NYSE:MDT) is a medical technology company that manufactures, distributes, and sells device-based medical services and therapies. It operates under four primary segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit.

3. Medline Inc. (NASDAQ:MDLN)

Analyst Upside: 48.25%

Medline Inc. (NASDAQ:MDLN) is one of the best healthcare stocks to buy with highest upside potential. Barclays cut the price target on Medline Inc. (NASDAQ:MDLN) to $45 from $50 on June 1, maintaining an Overweight rating on the shares. The firm stated that it believes factors such as inflationary pressure weighing on the margin outlook, less upside to fiscal Q1 estimates, and two secondaries have brought the company’s valuation “to a more palatable level.” According to Barclays, the stock is “poised for multiple expansion post war”, and it expects the company to “continue racking up share in the interim.”

Medline Inc. (NASDAQ:MDLN) also received a rating update from Tigress Financial on May 13. The firm lifted the price target on the stock to $62 from $60 while maintaining a Buy rating on the shares. It stated that the company’s ongoing transition from a traditional medical distributor to “a data-rich, AI-enabled supply chain partner” creates “near-term noise,” but “a long-term buying opportunity.”

Medline Inc. (NASDAQ:MDLN) provides medical-surgical products and supply chain solutions. The company’s operations are divided into the Medline Brand and Supply Chain Solutions segments.

2. Zoetis Inc. (NYSE:ZTS)

Analyst Upside: 50.85%

Zoetis Inc. (NYSE:ZTS) is one of the best healthcare stocks to buy with highest upside potential. Zoetis Inc. (NYSE:ZTS) received a rating update from Stifel on May 22. The firm cut the price target on the stock to $95 from $105 while maintaining a Hold rating on the shares, and told investors that the company’s revised 2026 guidance implies things improve, yet near-term competitive pressures “appear poised to intensify”.

Zoetis Inc. (NYSE:ZTS) also received a rating update from Argus on May 27, with the firm downgrading the stock to Hold from Buy. It told investors in a research note that the company’s stock price underwent a dramatic decline of 22% in a single day. It added that further losses thereafter reflected a lack of confidence among investors regarding the company’s growth prospects.

For reference, in its financial results for fiscal Q1 2026, Zoetis Inc. (NYSE:ZTS) reported revenue of $2.3 billion, up 3%, and net income of $601 million, or $1.42 per diluted share, flat and increasing 6%, respectively, on a reported basis. Adjusted net income for the quarter was $646 Million, or adjusted diluted EPS of $1.53.

Zoetis Inc. (NYSE:ZTS) is a global animal health company that focuses on the discovery, development, manufacture, and commercialization of vaccines, medicines, biodevices, genetic tests, diagnostic products, and precision animal health. Its operations are divided into the United States and International segments.

1. Boston Scientific Corporation (NYSE:BSX)

Analyst Upside: 61.53%

Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare stocks to buy with highest upside potential. TD Cowen cut the price target on Boston Scientific Corporation (NYSE:BSX) to $61 from $80 on May 29, maintaining a Buy rating on the shares and stating that the firm updated its model to account for the latest Watchman update and related variables. TD Cowen moved to the bottom of the company’s organic sales growth guidance for both Q2 and the full year.

Boston Scientific Corporation (NYSE:BSX) also received a rating update from BofA in a separate development. BofA cut the price target on Boston Scientific Corporation (NYSE:BSX) to $68 from $105 on May 18, reaffirming a Buy rating on the shares. The firm told investors that after having hosted 34 medtech companies last week in Las Vegas, it updated several price targets for “the new reality of medtech valuations” in a year of few product cycles, inflation kicking up post-war, ACA, and utilization worries, and “data centers over healthcare”.

Boston Scientific Corporation (NYSE:BSX) manufactures, develops, and markets medical devices used in interventional medical procedures. Its operations are divided into Cardiovascular and MedSurg segments. The Cardiovascular segment covers Cardiology and Peripheral Interventions, while the MedSurg segment comprises Urology, Endoscopy, and Neuromodulation.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.